Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when the company reports data from a late-stage trial of its treatment for ...

We recently published a list of 10 Top Performing European Stocks Heading into 2025. In this article, we are going to take a ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Good morning, and welcome to the Axsome Therapeutics Third ...

Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025 On track to initiate U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Thank you for standing by and welcome to Heron Therapeutics ...

Since 1999, MaxCyte's non-viral cell engineering innovations have helped launch pioneering cell and gene therapy projects. ROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- MaxCyt ...

Tharimmune, Inc. (NASDAQ:THAR) (”Tharimmune” or the “Company”), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today ...

CHAPEL HILL, N.C. (AP) — CHAPEL HILL, N.C. (AP) — Tenax Therapeutics Inc. (TENX) on Wednesday reported a loss of $4 million in its third quarter. On a per-share basis, the Chapel Hill, North ...

CARDIFF, Calif. (AP) — CARDIFF, Calif. (AP) — Viracta Therapeutics, Inc. (VIRX) on Wednesday reported a loss of $10.5 million in its third quarter. The Cardiff, California-based company said it had a ...

NEW YORK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of market insights and company news, proudly ...